1. INTRODUCTION

Genome editing tourism refers to individuals travelling to another country to obtain genetic modification procedures, particularly germline editing, reproductive interventions, or experimental gene therapies that are restricted or unavailable in their home jurisdiction.

Japan's regulatory approach seeks to prevent unsafe human genome-editing practices, protect reproductive health, and discourage the commercial exploitation of unproven genetic interventions. The distinction between somatic genome editing and heritable germline editing is central to its legal framework.

Japan does not impose a general prohibition on citizens travelling abroad for all genome-editing treatments. However, domestic restrictions apply to regulated activities conducted in Japan, and the 2026 legislation introduces specific restrictions on handling genome-edited human embryos and reproductive cells.

2. PRINCIPAL LEGAL FRAMEWORK

A. Act on Regulation of Handling of Human Genome-Edited Embryos, etc., 2026

Act No. 70 of 2026 was enacted in July 2026 and will enter into force on 24 July 2027.

Its principal provisions include:

Article 1: Protection of human life, physical safety, and future generations.

Article 3: Prohibition on implanting genome-edited human embryos and related materials into human or animal wombs, subject to a narrowly defined statutory exception.

Article 4: Governmental guidelines governing the handling of genome-edited embryos and related materials.

Regulatory requirements concerning creation, acquisition, importation, and use of regulated materials.

The legislation also introduces notification, supervision, inspection, and corrective-action mechanisms.

Importantly, the legislation does not establish a general criminal prohibition on Japanese citizens travelling overseas to receive genome-editing treatment.

B. Act on the Safety of Regenerative Medicine, 2013

This Act regulates regenerative medicine and relevant gene therapies conducted in Japan.

Following its May 2025 amendment, the framework also covers specified in-vivo gene therapies that do not use processed cells.

Medical institutions must satisfy applicable notification, safety-review, and treatment-supervision requirements.

C. Pharmaceuticals and Medical Devices Act

This legislation regulates the manufacture, marketing, and distribution of gene-therapy products and other regulated medical products.

Experimental or unapproved gene-editing products cannot automatically be marketed as authorised medical treatments.

D. Act on Regulation of Human Cloning Techniques, 2000

This legislation prohibits specified forms of embryo implantation associated with human cloning and regulates the creation, acquisition, and importation of certain embryos.

It complements Japan's broader reproductive biotechnology regulatory framework.

3. RESTRICTIONS ON GENOME-EDITING TOURISM

Japan's approach involves several important restrictions.

A. Germline Editing Restrictions

Heritable genome editing presents potential consequences for future generations. The 2026 Act establishes a binding domestic prohibition on specified embryo-handling and implantation activities.

B. Overseas Treatment and Jurisdiction

Japanese law does not automatically govern every medical procedure performed by a foreign clinic outside Japan. The applicability of Japanese criminal or regulatory legislation depends on territorial jurisdiction, statutory scope, and the conduct of the persons involved.

C. Commercial Advertising

Clinics must not misrepresent experimental procedures as established, approved, or guaranteed treatments. Misleading representations may attract liability under applicable consumer-protection and medical legislation.

D. Patient Protection

Patients should receive adequate information concerning scientific uncertainty, possible complications, treatment alternatives, and long-term consequences.

4. RELEVANT JUDICIAL DECISIONS

There are no established reported Japanese judgments specifically deciding genome-editing tourism or overseas CRISPR reproductive treatment. The following decisions provide analogous legal principles.

1. Jehovah's Witness Blood Transfusion Case (2000) – Analogous Medical Consent Authority

Supreme Court, 29 February 2000, Case No. 1998 (O) 1081.

The Court recognised a physician's liability for failing to explain the hospital's transfusion policy to a patient who had expressly refused blood transfusion. This decision supports informed consent requirements for experimental genetic interventions.

2. Tokai University Euthanasia Case (1995) – Analogous Medical Responsibility Authority

Yokohama District Court, 28 March 1995.

The judgment examined the legal boundaries of medical intervention and professional responsibility. Its principles are relevant when evaluating experimental procedures that exceed accepted medical practice.

3. Kawasaki Kyodo Hospital Case (2009) – Analogous Criminal Medical Liability Authority

Supreme Court, 7 December 2009.

The Court considered criminal responsibility arising from a physician's conduct during the withdrawal of life-support treatment. It demonstrates that medical professionals remain accountable for unlawful clinical decisions.

4. Itai-Itai Disease Case (1971) – Analogous Health Protection Authority

Toyama District Court, 30 June 1971.

The judgment recognised corporate responsibility for serious pollution-related health damage. It provides broader principles concerning foreseeable harm and preventive responsibility.

5. Niigata Minamata Disease Case (1971) – Analogous Scientific Causation Authority

Niigata District Court, 29 September 1971.

The judgment examined industrial pollution and resulting human health damage. Its approach to scientific causation may be relevant to claims involving adverse consequences of experimental genetic interventions.

6. Kansai Minamata Disease Case (2004) – Analogous Governmental Responsibility Authority

Supreme Court, 15 October 2004, Case No. 2001 (O) 1194.

The Court addressed governmental responsibility for failure to exercise available regulatory powers to prevent environmental health damage. Its reasoning is relevant to the importance of effective regulatory supervision.

These cases are analogous authorities, not direct precedents on genome-editing tourism.

5. INTERNATIONAL REGULATORY COOPERATION

Japan's policy is informed by international bioethics discussions and the need for responsible oversight of cross-border genetic research.

The World Health Organization's human genome-editing recommendations emphasise international cooperation, transparency, scientific responsibility, and prevention of unethical medical travel.

The International Commission on the Clinical Use of Human Germline Genome Editing has also highlighted the need for stringent scientific and ethical conditions before any reproductive application.

International cooperation is particularly important because domestic prohibitions cannot independently prevent individuals from seeking experimental procedures in jurisdictions with different regulatory standards.

6. PRACTICAL COMPLIANCE REQUIREMENTS

Japanese healthcare institutions, research organisations, and biotechnology companies should:

Distinguish somatic editing from heritable germline editing.

Verify the applicable Japanese statutory requirements before undertaking treatment or research.

Maintain appropriate ethical and scientific review.

Ensure transparent patient consent.

Verify regulatory approval of gene-therapy products.

Avoid misleading advertising concerning overseas experimental treatments.

Maintain appropriate adverse-event reporting and patient follow-up procedures.

Comply with the 2026 Human Genome-Edited Embryos Act when it commences in July 2027.

7. CONCLUSION

Japan's regulation of genome-editing tourism combines domestic biosafety legislation, regenerative medicine regulation, pharmaceutical controls, and emerging reproductive genome-editing restrictions.

The 2026 Act represents an important legislative development because it replaces the previous non-binding approach to specified heritable genome-editing activities with a statutory framework containing enforceable obligations and penalties.

Nevertheless, Japan does not impose a blanket prohibition on medical travel for every genome-editing intervention. The distinction between domestic prohibited conduct, overseas medical treatment, and cross-border regulatory jurisdiction remains essential. Japanese judicial decisions on informed consent, medical negligence, and governmental responsibility provide useful analogous principles for protecting patients and maintaining accountability in this developing area of biotechnology law.